Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-23
2011-08-23
Bowman, Amy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S006700, C514S006800, C514S006900
Reexamination Certificate
active
08003606
ABSTRACT:
Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for use in the described methods of treatment.
REFERENCES:
Evelyn et al. (Mol Cancer Ther, 2007, 6(8), pp. 2249-2260).
Iyer et al., “Serum response factor MADS box serine-162 phosphorylation switches proliferation and myogenic gene programs,” Proc. Natl. Acad. Sci., U.S.A., 103:4516-4521 (2006).
Rudich et al., “Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues,” Diabetologia, 46:649-658 (2003).
Sun et al., “Defining the mammalian CArGome,”Genome Res., 16:197-207 (2006).
Muehlich et al., “Serum-Induced Phosphorylation of the Serum Response Factor Coactivator MKL1 by the Extracellular Signal-Regulated Kinase 1/2 Pathway Inhibits Its Nuclear Localization,” Mol. Cell. Biol., 28:6302-6313 (2008).
Cooper et al., “Serum response factor binding sites differ in three human cell types,” Genome Res., 17(2):136-44 (2007).
Zhang et al., “Structural and Functional Analysis of Domains Mediating Interaction Between theBagpipeHomologue, Nkx3.1 and Serum Response Factor,” Exp. Biol. Med., 233(3):297-309 (2008).
Gurskaya et al., “DNA-binding antibiotics. X-ray structure of the distamycin A analog,” Biochim. Biophys. Acta., 563:336 (1979).
Rajagopalan et al., “Interaction of non-intercalative drugs with DNA: Distamycin analogues*,” J. Biosci., 7(1):27-32 (1985).
Sandbo et al., “Regulation of Serum Response Factor-Dependent Gene Expression by Proteasome Inhibitors,” Mol. Pharmacol., 67:789-797 (2005).
Elberg et al., “MKL1 mediates TGF-β1-induced α-smooth muscle actin expression in human renal epithelial cells,” Am. J. Physiol. Renal. Physiol., 294(5):F1116-28 (2008).
Nilsson et al., “Elk1 and SRF transcription factors convey basal transcription and mediate glucose response via their binding sites in the human LXRB gene promoter,” Nucleic Acids Res., 35(14):4858-68 (2007).
Chai et al., “Serum response factor is a critical requirement for VEGF signaling in endothelial cells and VEGF-induced angiogenesis,” FASEB J. 18(11):1264-6 (2004).
Schratt et al., “Serum Response Factor Is Required for Immediate-Early Gene Activation yet Is Dispensable for Proliferation of Embryonic Stem Cells,” Mol. Cell. Biol., 21(8):2933-43 (2001).
Kuwahara et al., “Muscle-Specific Signaling Mechanism That Links Actin Dynamics to Serum Response Factor,” Mol. Cell Biol., 25:3173-3181 (2005).
Martin et al., “Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study,” Lancet, 340:925-929 (1992).
Patti et al., “Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role ofPGC1andNRF1,” Proc. Natl. Acad. Sci. U.S.A., 100:8466-8471 (2003).
Mootha et al., “PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes,” Nat. Genet., 34:267-273 (2003).
Posern and Treisman, “Actin' together: serum response factor, its cofactors and the link to signal transduction,” Trends Cell. Biol., 16:588-596 (2006).
Brozinick et al., “Disruption of Cortical Actin in Skeletal Muscle Demonstrates an Essential Role of the Cytoskeleton in Glucose Transporter 4 Translocation in Insulin-sensitive Tissues,” J. Biol. Chem., 279:40699-40706 (2004).
Barres et al., “Enigma interacts with adaptor protein with PH and SH2 domains to control insulin-induced actin cytoskeleton remodelling and glucose transporter 4 translocation,” Mol. Endocrinol., 20:2864-2875 (2006).
Vartiainen et al., “Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofactor MAL,” Science, 316:1749-1752 (2007).
Miralles, “Actin dynamics control SRF activity by regulation of its coactivator MAL,” Cell, 113:329-342 (2003).
Sotiropoulos et al., “Signal-Regulated Activation of Serum Response Factor Is Mediated by Changes in Actin Dynamics,” Cell, 98:159-169 (1999).
Shoelson et al., “Inflammation and insulin resistance,” J. Clin. Invest., 116:1793-1801 (2006).
Tomas et al., “Regulation of pancreatic beta-cell insulin secretion by actin cytoskeleton remodelling: role of gelsolin and cooperation with the MAPK signalling pathway,” J. Cell. Sci., 119:2156-2167 (2006).
Selvaraj and Prywes, “Expression profiling of serum inducible genes identifies a subset of SRF target genes that are MKL dependent,” BMC. Mol Biol. 5:13 (2004).
Goldfine Allison B.
Jin Wanzhu
Patti Mary Elizabeth
Bowman Amy
Cox Niki D.
Joslin Diabetes Center, Inc.
Maraia Joseph M.
Pierce Atwood LLP
LandOfFree
Inhibiting serum response factor (SRF) to improve insulin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibiting serum response factor (SRF) to improve insulin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibiting serum response factor (SRF) to improve insulin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2635395